• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EBO
Click for more information
0.54% $34.79

Ebos Group Limited Ordinary Shares - Charts / Financials

watchlist Created with Sketch. Add to my watchlist
Healthcare

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Day
Open $34.89   Day High $34.90   Day Low $34.52
Daily Volume 181237
Bids   Sellers
Number Price Volume   Number Price Volume
0 $34.70 8000   0 $34.79 1538

Data source: Refinitiv

(20min delay)
Last
$34.79 		Change
-0.190(0.54%) 		Mkt cap ! n/a
Open High Low Value Volume
$34.89 $34.90 $34.52 $6.301M 181.2K

Buyers (Bids)

No. Vol. Price($)
0 8000 $34.70
 

Sellers (Offers)

Price($) Vol. No.
$34.79 1538 0
Last trade - 12.59pm 23/04/2024 (20 minute delay) ?

Top Stories

Are there gains to be made with the grocery giants?

There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
AML3D secures Australian defence government contract AML3D signed a contract with the Australian Government Defence Science and Technology Group (DSTG) to supply components for marine defence
Tamboran steps on the gas to supply the Top End Tamboran Resources has taken a significant step towards commercialising the gas resources of the Betaloo Sub Basin by signing a gas supply agreement with the Northern Territory Government.
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
PharmAust CEO's sayanora triggers stock plunge Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.